Akcea Therapeutics (AKCA) Misses Q4 EPS by 6c

Akcea Therapeutics (NASDAQ: AKCA) reported Q4 EPS of ($0.79), $0.06 worse than the analyst estimate of ($0.73). Revenue for the quarter came in at $10 million versus the consensus estimate of $17.76 million.

For earnings history and earnings-related data on Akcea Therapeutics (AKCA) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Investing.com’s stocks of the week
• UBS says bull market has further to run